The Leukemia & Lymphoma Society of Rye Brook will provide Poland-based Selvita S.A. with up to $3.25 million over four years to develop SEL120 as a treatment for acute myeloid leukemia. The Biotechnology Accelerator Division will help provide additional funding for further development of the SEL120 project.
AML drug candidate secures $3.2 million in funding
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.